Form 10-Q · Quarterly report
Johnson & Johnson 10-Q, filed Jul 23, 2026
- Filed
- CIK
- 0000200406
- Accession no.
- 0000200406-26-000153
Summary
Johnson & Johnson reported fiscal first-half 2026 worldwide sales of $49.4 billion, up 8.2% from a year earlier, and fiscal second-quarter sales of $25.3 billion, up 6.6%, with biosimilar competition for STELARA cutting operational sales growth by roughly 5.0% and 4.6% in those periods. The company said it expects STELARA biosimilars to continue reducing its STELARA sales, and that SIMPONI biosimilars entered the European market in the second quarter of 2026 with a potential U.S. entrant later in 2026.
Key points
- Innovative Medicine segment sales were $31.8 billion in the fiscal first half, up 9.4%, and $16.4 billion in the fiscal second quarter, up 7.8%.
- TREMFYA sales rose 70.6% to $3.65 billion in the fiscal first half, while STELARA sales fell 57.4% to $1.40 billion.
- CARVYKTI sales rose 55.1% to $1.25 billion and DARZALEX rose 20.6% to $8.17 billion in the fiscal first half.
- SIMPONI biosimilars entered the European market in the second quarter of 2026, with a potential U.S. entrant later in 2026.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2 — Management’s discussion Results of operations Sales to customers Analysis of consolidated sales For the fiscal six months of 2026, worldwide sales were $49.4 billion, a total increase of 8.2%, including an operational* increase of 6.0% as compared to 2025 fiscal six months sales of $45.6 billion. Currency fluctuations had a positive impact of 2.2% for the fiscal six months of 2026. In the fiscal six months of 2026, acquisitions and divestitures had net positive impact of 0.5%, on worldwide operational sales growth, primarily related to CAPLYTA. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.